KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  title={KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib},
  author={William Pao and Theresa Y Wang and Gregory J Riely and Vincent A. Miller and Qiulu Pan and Marc Ladanyi and Maureen F. Zakowski and Robert T. Heelan and Mark G. Kris and H. E. Varmus},
  journal={PLoS Medicine},
  pages={2129 - 2139}
BACKGROUND Somatic mutations in the gene for the epidermal growth factor receptor (EGFR) are found in adenocarcinomas of the lung and are associated with sensitivity to the kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Lung adenocarcinomas also harbor activating mutations in the downstream GTPase, KRAS, and mutations in EGFR and KRAS appear to be mutually exclusive. METHODS AND FINDINGS We sought to determine whether mutations in KRAS could be used to further enhance… CONTINUE READING
Highly Influential
This paper has highly influenced 45 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 695 extracted citations

Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.

Cancer immunology research • 2016
View 10 Excerpts
Highly Influenced

Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma.

Cancer control : journal of the Moffitt Cancer Center • 2015
View 5 Excerpts
Highly Influenced

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology • 2009
View 8 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 13 references

Statistics with confidence, 2nd ed. London: BMJ Books

DG Altman, D Machin, TN Bryant, MJ Gardner
View 1 Excerpt

Similar Papers

Loading similar papers…